Viewing Study NCT00329056



Ignite Creation Date: 2024-05-05 @ 4:50 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00329056
Status: COMPLETED
Last Update Posted: 2010-07-21
First Post: 2006-05-22

Brief Title: A Trial of MitoQ for the Treatment of People With Parkinsons Disease
Sponsor: Antipodean Pharmaceuticals Inc
Organization: Antipodean Pharmaceuticals Inc

Study Overview

Official Title: A Double-Blind Prospective Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinsons Disease
Status: COMPLETED
Status Verified Date: 2010-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In Parkinsons Disease the mitochondrial membranes in cells that produce dopamine become damaged by oxidants leading to the death of these cells and progressive tremor slowness of movement and the loss of neurons in the substantia nigra a part of the brain that is involved in movement Mitoquinone is targeted to reach the membrane of mitochondria and provide protection from damaging oxidants There are no treatments currently available to slow the progression of PD and this trial will help advance the development of this unique disease modifying drug

This trial will enroll 120 participants with untreated early onset of PD Participants will be randomized to receive 1 of 3 treatments 40 mg of MitoQ tablets 80 mg of MitoQ tablets or placebo The researchers participants and sponsor will all be blinded to the treatment allocation Participants will be assessed after 1 2 3 6 9 12 months of treatment and again 28 days after their last dose The effectiveness of the trial drug will be measured via the Unified Parkinsons Disease Rating Scale UPDRS The safety of the trial drug will be monitored via regular participant examinations blood tests ECG and collecting information on adverse events
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None